Ikarian Capital’s Anebulo Pharmaceuticals ANEB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-17,736
| Closed | -$17.9K | – | 167 |
|
|
2025
Q4 | $17.9K | Sell |
17,736
-139,984
| -89% | -$319K | ﹤0.01% | 173 |
|
|
2025
Q3 | $394K | Hold |
157,720
| – | – | 0.04% | 143 |
|
|
2025
Q2 | $227K | Hold |
157,720
| – | – | 0.04% | 109 |
|
|
2025
Q1 | $205K | Hold |
157,720
| – | – | 0.03% | 139 |
|
|
2024
Q4 | $265K | Sell |
157,720
-142
| -0.1% | -$234 | 0.04% | 145 |
|
|
2024
Q3 | $305K | Hold |
157,862
| – | – | 0.04% | 128 |
|
|
2024
Q2 | $431K | Hold |
157,862
| – | – | 0.08% | 97 |
|
|
2024
Q1 | $453K | Hold |
157,862
| – | – | 0.05% | 122 |
|
|
2023
Q4 | $382K | Hold |
157,862
| – | – | 0.04% | 119 |
|
|
2023
Q3 | $504K | Buy |
157,862
+1,659
| +1% | +$4.6K | 0.06% | 113 |
|
|
2023
Q2 | $341K | Hold |
156,203
| – | – | 0.05% | 104 |
|
|
2023
Q1 | $462K | Hold |
156,203
| – | – | 0.1% | 98 |
|
|
2022
Q4 | $375K | Hold |
156,203
| – | – | 0.09% | 62 |
|
|
2022
Q3 | $437K | Sell |
156,203
-24,996
| -14% | -$88.8K | 0.09% | 87 |
|
|
2022
Q2 | $942K | Hold |
181,199
| – | – | 0.17% | 78 |
|
|
2022
Q1 | $1.23M | Buy |
181,199
+8,890
| +5% | +$60.9K | 0.16% | 91 |
|
|
2021
Q4 | $1.07M | Hold |
172,309
| – | – | 0.16% | 99 |
|
|
2021
Q3 | $1.16M | Sell |
172,309
-2,502
| -1% | -$17.5K | 0.08% | 153 |
|
|
2021
Q2 | $1.2M | Buy |
+174,811
| New | +$1.3M | 0.1% | 152 |
|
Ikarian Capital's ANEB Position: Q1 2026 in Review
Ikarian Capital sold out of Anebulo Pharmaceuticals (ANEB) in Q1 2026, closing a stake of 17,736 shares — an estimated $17.9K sold.
Ikarian Capital first reported a position in ANEB in Q2 2021 and held it in 19 quarters. The position peaked at $1.23M in Q1 2022. 0 funds tracked by Wall St. Rank hold ANEB as of Q1 2026.
- Ikarian Capital reported no remaining Anebulo Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Ikarian Capital sold 17,736 Anebulo Pharmaceuticals shares in Q1 2026, an estimated $17.9K.
- Ikarian Capital first reported a position in Anebulo Pharmaceuticals in Q2 2021 and held it in 19 quarters.
- Ikarian Capital's Anebulo Pharmaceuticals position peaked at $1.23M in Q1 2022.
- 0 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q1 2026.
Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.